{"id":1068358,"date":"2023-03-23T00:21:50","date_gmt":"2023-03-23T04:21:50","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/acumen-pharmaceuticals-to-participate-in-stifel-2023-virtual-cns-days\/"},"modified":"2024-08-18T11:46:18","modified_gmt":"2024-08-18T15:46:18","slug":"acumen-pharmaceuticals-to-participate-in-stifel-2023-virtual-cns-days","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/acumen-pharmaceuticals-to-participate-in-stifel-2023-virtual-cns-days.php","title":{"rendered":"Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days"},"content":{"rendered":"<p><![CDATA[CHARLOTTESVILLE, Va. and CARMEL, Ind., March  22, 2023  (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer\u2019s disease, announced today that management will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on\u00a0Wednesday, March 29, 2023\u00a0at\u00a012:30 p.m. ET. The live webcast may be accessed under the Investors tab on\u00a0www.acumenpharm.com\u00a0and will be archived for 14 days.]]><\/p>\n<p>Read the original post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2023\/03\/22\/2632692\/0\/en\/Acumen-Pharmaceuticals-to-Participate-in-Stifel-2023-Virtual-CNS-Days.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days\">Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read the original post: Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/acumen-pharmaceuticals-to-participate-in-stifel-2023-virtual-cns-days.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068358","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068358"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068358"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068358\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}